Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

This study has been terminated.
(Low accrual rate)
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier:
NCT01339039
First received: April 6, 2011
Last updated: March 29, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2016
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)